vs
阿普塔集团（ATR）与EPAM Systems（EPAM）财务数据对比。点击上方公司名可切换其他公司
EPAM Systems的季度营收约是阿普塔集团的1.5倍（$1.4B vs $962.7M），EPAM Systems净利率更高（7.8% vs 7.7%，领先0.0%），阿普塔集团同比增速更快（13.5% vs 12.8%），EPAM Systems自由现金流更多（$268.1M vs $96.9M），过去两年EPAM Systems的营收复合增速更高（9.9% vs 2.6%）
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
EPAM Systems是总部位于美国宾夕法尼亚州纽敦的企业，核心业务涵盖软件工程服务、数字平台研发、数字产品设计三大板块，同时是MACH联盟的创始成员，在全球数字化服务赛道拥有深厚的技术积累与行业认可度。
ATR vs EPAM — 直观对比
营收规模更大
EPAM
是对方的1.5倍
$962.7M
营收增速更快
ATR
高出0.8%
12.8%
净利率更高
EPAM
高出0.0%
7.7%
自由现金流更多
EPAM
多$171.2M
$96.9M
两年增速更快
EPAM
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $962.7M | $1.4B |
| 净利润 | $74.3M | $109.4M |
| 毛利率 | — | 30.1% |
| 营业利润率 | 11.0% | 10.6% |
| 净利率 | 7.7% | 7.8% |
| 营收同比 | 13.5% | 12.8% |
| 净利润同比 | -26.4% | 5.9% |
| 每股收益（稀释后） | $1.13 | $1.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATREPAM
| Q4 25 | $962.7M | $1.4B | ||
| Q3 25 | $961.1M | $1.4B | ||
| Q2 25 | $966.0M | $1.4B | ||
| Q1 25 | $887.3M | $1.3B | ||
| Q4 24 | $848.1M | $1.2B | ||
| Q3 24 | $909.3M | $1.2B | ||
| Q2 24 | $910.1M | $1.1B | ||
| Q1 24 | $915.4M | $1.2B |
净利润ATREPAM
| Q4 25 | $74.3M | $109.4M | ||
| Q3 25 | $127.9M | $106.8M | ||
| Q2 25 | $111.7M | $88.0M | ||
| Q1 25 | $78.8M | $73.5M | ||
| Q4 24 | $100.9M | $103.3M | ||
| Q3 24 | $100.0M | $136.3M | ||
| Q2 24 | $90.5M | $98.6M | ||
| Q1 24 | $83.1M | $116.2M |
毛利率ATREPAM
| Q4 25 | — | 30.1% | ||
| Q3 25 | — | 29.5% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | — | 26.9% | ||
| Q4 24 | — | 30.4% | ||
| Q3 24 | — | 34.6% | ||
| Q2 24 | — | 29.3% | ||
| Q1 24 | — | 28.4% |
营业利润率ATREPAM
| Q4 25 | 11.0% | 10.6% | ||
| Q3 25 | 14.2% | 10.4% | ||
| Q2 25 | 14.9% | 9.3% | ||
| Q1 25 | 12.8% | 7.6% | ||
| Q4 24 | 14.2% | 10.9% | ||
| Q3 24 | 15.2% | 15.2% | ||
| Q2 24 | 13.8% | 10.5% | ||
| Q1 24 | 12.2% | 9.5% |
净利率ATREPAM
| Q4 25 | 7.7% | 7.8% | ||
| Q3 25 | 13.3% | 7.7% | ||
| Q2 25 | 11.6% | 6.5% | ||
| Q1 25 | 8.9% | 5.6% | ||
| Q4 24 | 11.9% | 8.3% | ||
| Q3 24 | 11.0% | 11.7% | ||
| Q2 24 | 9.9% | 8.6% | ||
| Q1 24 | 9.1% | 10.0% |
每股收益（稀释后）ATREPAM
| Q4 25 | $1.13 | $1.97 | ||
| Q3 25 | $1.92 | $1.91 | ||
| Q2 25 | $1.67 | $1.56 | ||
| Q1 25 | $1.17 | $1.28 | ||
| Q4 24 | $1.48 | $1.80 | ||
| Q3 24 | $1.48 | $2.37 | ||
| Q2 24 | $1.34 | $1.70 | ||
| Q1 24 | $1.23 | $1.97 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $409.5M | $1.3B |
| 总债务越低越好 | $1.1B | — |
| 股东权益账面价值 | $2.7B | $3.7B |
| 总资产 | $5.3B | $4.9B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资ATREPAM
| Q4 25 | $409.5M | $1.3B | ||
| Q3 25 | $264.8M | $1.2B | ||
| Q2 25 | $169.8M | $1.0B | ||
| Q1 25 | $136.8M | $1.2B | ||
| Q4 24 | $226.2M | $1.3B | ||
| Q3 24 | $327.9M | $2.1B | ||
| Q2 24 | $223.9M | $1.8B | ||
| Q1 24 | $201.1M | $2.0B |
总债务ATREPAM
| Q4 25 | $1.1B | — | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | — | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — | ||
| Q1 24 | $680.4M | — |
股东权益ATREPAM
| Q4 25 | $2.7B | $3.7B | ||
| Q3 25 | $2.8B | $3.7B | ||
| Q2 25 | $2.7B | $3.7B | ||
| Q1 25 | $2.5B | $3.6B | ||
| Q4 24 | $2.5B | $3.6B | ||
| Q3 24 | $2.5B | $3.6B | ||
| Q2 24 | $2.4B | $3.4B | ||
| Q1 24 | $2.3B | $3.5B |
总资产ATREPAM
| Q4 25 | $5.3B | $4.9B | ||
| Q3 25 | $5.1B | $4.8B | ||
| Q2 25 | $4.9B | $4.7B | ||
| Q1 25 | $4.5B | $4.7B | ||
| Q4 24 | $4.4B | $4.8B | ||
| Q3 24 | $4.6B | $4.5B | ||
| Q2 24 | $4.5B | $4.2B | ||
| Q1 24 | $4.4B | $4.4B |
负债/权益比ATREPAM
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.7M | $282.9M |
| 自由现金流经营现金流 - 资本支出 | $96.9M | $268.1M |
| 自由现金流率自由现金流/营收 | 10.1% | 19.0% |
| 资本支出强度资本支出/营收 | 9.0% | 1.1% |
| 现金转化率经营现金流/净利润 | 2.47× | 2.59× |
| 过去12个月自由现金流最近4个季度 | $299.6M | $612.7M |
8季度趋势，按日历期对齐
经营现金流ATREPAM
| Q4 25 | $183.7M | $282.9M | ||
| Q3 25 | $177.6M | $294.7M | ||
| Q2 25 | $126.0M | $53.2M | ||
| Q1 25 | $82.7M | $24.2M | ||
| Q4 24 | $178.2M | $130.3M | ||
| Q3 24 | $229.3M | $242.0M | ||
| Q2 24 | $143.6M | $57.0M | ||
| Q1 24 | $92.3M | $129.9M |
自由现金流ATREPAM
| Q4 25 | $96.9M | $268.1M | ||
| Q3 25 | $114.3M | $286.4M | ||
| Q2 25 | $62.5M | $43.4M | ||
| Q1 25 | $25.9M | $14.8M | ||
| Q4 24 | $112.2M | $114.5M | ||
| Q3 24 | $162.7M | $237.0M | ||
| Q2 24 | $75.4M | $52.3M | ||
| Q1 24 | $16.7M | $123.2M |
自由现金流率ATREPAM
| Q4 25 | 10.1% | 19.0% | ||
| Q3 25 | 11.9% | 20.5% | ||
| Q2 25 | 6.5% | 3.2% | ||
| Q1 25 | 2.9% | 1.1% | ||
| Q4 24 | 13.2% | 9.2% | ||
| Q3 24 | 17.9% | 20.3% | ||
| Q2 24 | 8.3% | 4.6% | ||
| Q1 24 | 1.8% | 10.6% |
资本支出强度ATREPAM
| Q4 25 | 9.0% | 1.1% | ||
| Q3 25 | 6.6% | 0.6% | ||
| Q2 25 | 6.6% | 0.7% | ||
| Q1 25 | 6.4% | 0.7% | ||
| Q4 24 | 7.8% | 1.3% | ||
| Q3 24 | 7.3% | 0.4% | ||
| Q2 24 | 7.5% | 0.4% | ||
| Q1 24 | 8.3% | 0.6% |
现金转化率ATREPAM
| Q4 25 | 2.47× | 2.59× | ||
| Q3 25 | 1.39× | 2.76× | ||
| Q2 25 | 1.13× | 0.60× | ||
| Q1 25 | 1.05× | 0.33× | ||
| Q4 24 | 1.77× | 1.26× | ||
| Q3 24 | 2.29× | 1.77× | ||
| Q2 24 | 1.59× | 0.58× | ||
| Q1 24 | 1.11× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
EPAM
暂无分部数据
